Ειδήσεις: WEIGHT‑LOSS DRUG | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

31/03 17:58 inc.com

Novo Nordisk Slashes Wegovy Prices by 30%, With 2 Major Caveats for Patients

Novo Nordisk Wegovy price cut telehealth Eli Lilly weight‑loss drug

24/03 08:48 timesnownews.com

Centre Cracks Down on Weight Loss Drugs: GLP-1 Sale Now Under Strict Surveillance

India GLP‑1 weight‑loss drugs drug regulation pharmaceutical oversight DCGI

22/03 16:00 okmagazine.com

Hollywood Weight Loss Jabs Shocker — How Fat-Fighting Drugs Could Leave the World's Biggest Stars With Painful Complications

Hollywood weight‑loss drugs bone injuries tendon complications celebrity health medical risks

19/03 18:21 statnews.com

STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.

Novo Nordisk Wegovy high‑dose FDA voucher obesity treatment market share

17/03 20:28 marketwatch.com

Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales

Lilly GLP‑1 Zepbound downgrade AI job loss weight‑loss drugs

17/03 20:28 marketwatch.com

Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales

Lilly GLP‑1 Zepbound downgrade AI job loss weight‑loss drugs

Loading...